SRRKScholar Rock Holding Corporation

Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing

Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance. One is smoothly navigating a supply chain hurdle ahead of a critical drug approval, while the other just delivered a complicated financial quarter. The contrast reveals how investors weigh proactive execution against noisy financial […]

Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second parag

Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the company prepares for a potential launch of the muscle-targeted treatment for spinal muscular atrophy, or

Scholar Rock Holding Corp (SRRK) reports strong cash position and progress toward apitegromab approval, with two independent fill-finish facilities providing regulatory optionality.

Scholar Rock Holding (SRRK) stock has drawn fresh attention after recent trading performance, with shares last closing at $49.37 on 28 July 2026. Investors are weighing this price against the company’s longer term return profile. See our latest analysis for Scholar Rock Holding. Over the past month the stock has pulled back, with a 30 day share price return of down 9.84%. However, the year to date share price return of 15.35% and the very large 3 year total shareholder return of more than 6x...

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.